Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.

logo of Zymeworks
Portfolio company

Zymeworks

Details
Region
Prairies and West
Industry sector
Drugs
Investment year
2016
Fund
Healthcare Venture Fund
Learn More
About the company

Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. The company’s novel Azymetric™, AlbuCORE™, and EFECT™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.

Our partnership

Zymeworks is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.

Contact

Dion Madsen, Founding partner at Amplitude Venture Capital.